Treatment for Obsessive-Compulsive Disorder

Phase-Based Progress Estimates

Effectiveness

Safety

The University of Texas at Austin, Austin, TX

Obsessive-Compulsive Disorder+9 More

You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.

Eligibility

18+

All Sexes

What conditions do you have?

Select

Eligibility

18+

All Sexes

What conditions do you have?

Select

Study Summary

Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question "can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?"

Eligible Conditions

Obsessive-Compulsive Disorder
Phobia, Social
Anxiety Disorders
Panic Attacks
Post Traumatic Stress Disorder (PTSD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Bibliotherapy, low therapist contact SPACE

Active Treatment (HB-01)

Exposure Therapy

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: Weekly for 14 weeks + follow-up after 24 weeks

Week 13 (post-treatment)

Non-response to exposure-based therapy

Week 24

Clinical Global Impression (CGI)

Clinical Global Impression - Severity of Illness (CGI-S)

Dimensional Obsessive-Compulsive Scale (DOCS)

GAD-7

Overall Anxiety Severity and Impairment Scale (OASIS)

PTSD Checklist for DSM-5 (PCL-5)

Panic Disorder Severity Scale (PDSS)

Social Phobia Inventory (SPIN)

Trial Safety

Safety Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Bibliotherapy, low therapist contact SPACE

Active Treatment (HB-01)

Exposure Therapy

Trial Design

0 Treatment Group

600 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline

Screening: ~3 weeks

Treatment: Varies

Reporting: weekly for 14 weeks + follow-up after 24 weeks

Closest Location: The University of Texas at Austin · Austin, TX

2006First Recorded Clinical Trial

1 TrialsResearching Obsessive-Compulsive Disorder

24 CompletedClinical Trials

Who is running the clinical trial?

Boston UniversityOTHER

410 Previous Clinical Trials

10,023,144 Total Patients Enrolled

National Institute of Mental Health (NIMH)NIH

2,489 Previous Clinical Trials

1,765,310 Total Patients Enrolled

59 Trials studying Obsessive-Compulsive Disorder

12,367 Patients Enrolled for Obsessive-Compulsive Disorder

University of Texas at AustinLead Sponsor

283 Previous Clinical Trials

66,641 Total Patients Enrolled

2 Trials studying Obsessive-Compulsive Disorder

161 Patients Enrolled for Obsessive-Compulsive Disorder

Jasper Smits, Ph.D.Principal InvestigatorThe University of Texas at Austin

3 Previous Clinical Trials

132 Total Patients Enrolled

Michael Otto, Ph.D.Principal InvestigatorBoston University

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

You have a score of 8 or greater on the OASIS.

You are proficient in English.

You are willing and able to provide informed consent and comply with the requirements of the study protocol.

About The Reviewer

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References